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Abstract
The 3,4,5-trimethoxyphenyl motif is a common structural feature of a number of natural occurring
antimitotic agents, especially those capable interacting with microtubules such as the cis-stilbene,
combrestatin A-4. Chalcones possessing this pharmacophore have likewise been demonstrated to exhibit
a diverse range of biological actions including anticancer, anti-invasive, antioxidant, and antiinflammatory activities. As part of an experiential learning experience in academic drug discovery
termed WSU PharmaFlights, so-called flights of 6-10 molecules based on a particular biologically
relevant structural pattern on the privileged chalcone scaffold are to be designed, synthesized, and
spectroscopically characterized as a starting point for lead-development with potential biological
collaborators. In this paradigm, students are assigned a specific pharmacophore group on either ring A
or B of the chalcone nucleus, assess the scope of activities associated with that fragment and propose
fragments on the alternate ring likely to produce enhanced or dual function activity against certain
therapeutic or diagnostic targets. This specific project involves the rational design of a flight of
chalcones displaying the 3,4,5-trimethoxyphenyl moiety on ring B, and a discussion of the potential
applications of this lead discovery library.

Introduction
In the most general of terms, the medicinal chemistry paradigm can be viewed as the progression
from identification of a lead compound (a molecule exhibiting the desired biological effect) to the actual
drug by optimizing beneficial effects in a rational manner while minimizing deleterious effects. Where
no such lead may be apparent, a convenient starting point can be the use of so-called privileged
scaffolds, classes of molecules capable of binding to ligands of multiple unrelated class of receptors.1-3
While such promiscuity may eventually prevent realization of the intended goal, it is expected that if the
desired activity/selectivity cannot be achievable with that class of compounds, sufficient structure
activity relationships (SAR) might be developed so as to allow for the translation (scaffold hopping) of

the beneficial fragments (pharmacophores) to a more druglike scaffold capable of allowing for
development into an actual drug.
Since it is reasonable to expect that libraries prepared such around such privileged scaffolds are
more likely to generate a lead compound than those prepared from non-privileged structures, the Ketcha
Group at WSU has chosen to focus on the chalcone core structure as the scaffold of interest and the
starting point for prospective studies based on the known biological activities attributable to certain
structural features. Chalcones (1,3-diaryl-2-propn-1-ones) are a class of open-chain flavonoids in which
two aromatic rings are linked by a three carbon -unsaturated carbonyl system. Such molecules are
easily prepared by the base-catalyzed Claisen-Schmidt condensation involving readily available
acetophenone and aryl aldehyde precursors.

Given the ease of preparation from low cost building blocks and the wide variety of biological
functions attributable to this core ranging from anticancer, anti-inflammatory, anti-oxidant, to antimicrobial, anti-malarial, and anti-HIV,4 chalcones were visualized as an excellent starting point for an
experiential learning experience for undergraduate research students in medicinal chemistry and
academic drug discovery termed PharmaFlights. In this paradigm, the students are asked to research a
particular pharmacophore on either ring, explore the scope of biological activities attributable to that
fragment, and suggest variants of the alternate ring and prepare flights of 5-10 molecules expected to
serve as leads for a particular diagnostic area.

The pharmacophore of interest for this PharmaFlight project is the 3,4,5-trimethoxy moiety on
Ring B. This particular motif is most commonly associated with anticancer activity, as it is present in a
variety of naturally-occurring anti-mitotic agents such as colchicine (3)5 and combrestatin A-4 (4)6 both
of which are believed to exert their effects by blocking β-tubulin formation at the colchicine binding
site.7 Given the structural similarity between the cis-stilbene combrestatin A-4 and the chalcone nucleus
(varying only in a C=O carbonyl adjacent to the double bond), it is not surprising that chalcones with a
3,4,5-trimethoxy pharmacophore have been found to display anticancer,4,9,10-16 anti-mitotic,2,8,17
antioxidant/anti-inflammatory,12,18-24 anti-proliferative,9,14,17-18,25 and anti-angiogenesis activities,25 in
addition to applications as anti-bacterial,24,26-27 anti-microbial,28 anti-parasitic,29 anti-invasive,30 and
cardiovascular agents.17,31

Since the finding in 1990 that chalcone 5 possessing the trimethoxy motif on ring A was more
potent than colchicine in tumor test systems in mice,2 most studies involving the anticancer effects of
chalcones have focused on the 3`,4`,5`-trimethoxy fragment. However, the authors note that when the
substituents on the two rings are reversed (e.g., 6), moderate activity was retained.2 While such
“reversed” analogues are often observed to retain some or most of the activity associated with the
original, such observations (though not axiomatic) serve as the basis for the present flight of molecules
based upon the less studied 3,4,5-trimethoxy moiety on Ring B.

While in this work of the Ring A trimethoxy-substituted chalcones, it was observed that the
highest activity was observed when the strongly electron-donating (EDG) dimethylamino group was at
position 4 of Ring B, whereas activity was lost by substituting this group with the strongly electronwithdrawing (EWG) 4-nitro group. Incongruously, in a 2010 publication on the anticancer, antiinflammatory, and antioxidant activities of chalcones possessing the 3,4,5-trimethoxy substituents on
Ring B, it found that highest activity was attributable to an EWG 4`-nitro group on ring A.12 Moreover,
the second most active analog was found to be associated with an EDG 4`-methoxy substituent at that
position. The major question for optimal anticancer activity then becomes whether EDG or EWG Ring
A is a more efficient fragment on the aromatic ring. For this particular project, the EWG functional
groups wanted to be explored further in the flight of compounds.
The first compound of this flight of molecules serves as the basis of inspiration for the rest of the
molecules in this flight. Possessing a 4`-nitro group on Ring A (7), this compound was found to be
effective against five different cancer cell lines, as well as exhibit antioxidant and anti-inflammatory
behavior.12 Most of the molecules in this flight are designed to mimic the structural components of this
chalcone by substituting an (EWG) on Ring A, in the hopes that they may also exhibit multi-functional
activities as well, such as being anticancer and antioxidant. Another type EWG that was to be explored
is fluorine, as they possess many advantages when paired with chalcones: being both lipophilic and
having a high electronegativity, fluorinated chalcones are more resistant to metabolic processes and are
more soluble in lipids, overall increasing the effectiveness as a potential drug.14 Similarly, a 4`-fluoro3,4,5-trimethoxy chalcone (8) was found to inhibit nitric oxide (NO) production by limiting inducible
nitric oxide synthase (iNOS), ultimately making the molecule both antioxidant and anti-inflammatory to
an extent.21-22 In addition, this same molecule also expressed anti-invasive activity against a chicken

heart cell assay.30 Increasing the number of fluorines on Ring A could also enhance the activity further;
it was shown that the 2,5-difluoro substituted Ring B with a 2`,4`,6`-trimethoxy fragment on Ring A
showed promising anti-proliferative activity.14 Altering the trimethoxy pattern from 2`,4`,6`- to 3,4,5and switching the 2,5- difluoro substituent to Ring A could show similar (if not identical) activity (9),
leading to its inclusion in the flight of compounds. Because the 2’-fluoro position was shown to be a
powerful motif in fluorinated chalcones,14 a similar chalcone utilizing a more symmetric 2`,6`- difluoro
substitution on Ring A (10) was also included in the flight of compounds. Because trifluoro chalcones
are not commonly represented in literature, utilizing a trifluoromethyl group serves as an effective way
to introduce three fluorine atoms to the chalcone, while also potentially providing additional biological
activity to the chalcone, as the 2`-trifluoromethyl moiety on chalcones (11) has been known to inhibit
interleukin-1 generation, showing anti-oxidant behavior as a result.32 The 2`-pyridyl moiety was also
considered for this flight (12), as an electron-deficient pyridine ring is as effective as a benzene ring with
an EWG, and unlike the nitro group, it provides another potential opportunity for hydrogen bonding
within the molecule. The 2`-pyridyl-3,4,5-trimethoxy chalcone has been known to exhibit antibacterial
and antifungal activity in a prior study.33 For the final molecule, the issue of anticancer properties
associating with conflicting EWG or EDG felt needed to be addressed. Because nitro chalcones can be
referred to as bioreductively activatable prodrugs,11 the EDG 4`-amino (13) group was included in this
flight as well, as it has also exhibited anticancer and antioxidant activities.11,34 It is the hope that the
biological activities of each of these Ring A substituents could complement the activities of the 3,4,5trimethoxy motif in yielding a multi-functional hybrid lead compound that can serve as a starting point
for a potential drug.

For the next flight of molecules, various different substituents on Ring A would be considered
for exploration, particularly other types of EWG, and introducing more EDG fragments as well. The
pyridyl moiety would like to be investigated further, so future compounds could utilize the 3`-pyridyl
and 4`-pyridyl substituents. 4`-dimethylamino is an EDG that would also like to be explored, as it is a
known tubulin polymerization inhibitor.2 A large emphasis of an ortho-fluorine configuration can lead to
a 2`-fluoro fragment on Ring A as another potential future 3,4,5- trimethoxy chalcone.14 Finally, another
EWG that has yet to be explored by this lab group is a hydroxyl group (-OH), so a 2`-hydroxyl and a 4`hydroxyl 3,4,5- trimethoxy chalcone could serve as another candidate for the future flight of chalcones.
Experimental Procedures
General Procedure A: To a vial equipped with a stir bar and containing ethanol (8 mL) was added
3,4,5-trimethoxybenzaldehyde (2.5 mmol) and stirred for 30 minutes to effect near complete dissolution,
at which time 10% NaOH (1 mL) was added slowly dropwise changing the clear solution to a paleyellow color. The mixture was then placed in an ice bath for 5 min and variously-substituted
acetophenones (2.5 mmol) as a suspension in ethanol (5 mL) were added dropwise.

General Procedure B: To a vial equipped with a stir bar and containing ethanol (2.5 mL) at 62.3ºC was
added 3,4,5-trimethoxybenzaldehyde (0.4900 g, 2.49 mmol) and the mixture was stirred for 10 min to
effect dissolution. At that time, 10% NaOH (1 mL) was added slowly dropwise changing the clear
solution to a yellow color. The sample was then removed from heating and stirred for 10 min at rt
whereupon variously-substituted acetophenones (2.5 mmol) were added slowly dropwise.
1-(4-Nitro)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7) <CF 1-32>
General Procedure A was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4911 g, 2.5 mmol) and
4-nitroacetophenone (0.4150 g, 2.5 mmol) to afford a solution of a dark red color with an orange
precipitate. After two hours, the darkened solution was filtered by vacuum filtration to provide the
product (0.1717 g, 20%) as a yellow solid: mp 150-152ºC (lit. mp10 136ºC); Rf 0.63 (1:1
EtOAc/Hexane); GC/MS at 96.8% pure (M+ 343.1); 1H (300.13 MHz, CDCl3) δ 3.93 (s, 3H, OCH3),
3.94 (s, 6H, OCH3), 6.89 (s, 2H, 2-H), 7.37 (d, J = 15.6 Hz, 1H, α-H), 7.77 (d, J = 15.6 Hz, 1H, β-H),
8.15 (d, J = 8.9 Hz, 2H, 2`-H), 8.37 (d, J = 8.9 Hz, 2H, 3`-H).
1-(4-Fluoro)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (8) <CF 1-65>
General Procedure A was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4948 g, 2.52 mmol) and
4-fluoroacetophenone (300 µL, 2.5 mmol) to afford solution of a bright yellow color. After 30 min, the
solution was filtered by vacuum filtration to provide the product (0.5308 g, 67%) as a white solid: mp
97-99ºC (lit. mp15 108-109ºC); Rf 0.80 (1:1 EtOAc/Hexane); GC/MS at 100% pure (M+ 316.1); 1H
(300.13 MHz, CDCl3) δ 3.92 (s, 3H, OCH3), 3.94 (s, 6H, OCH3), 6.88 (s, 2H, 2-H), 7.19 (t, J = 8.7 Hz,
2H, 3`-H), 7.39 (d, J = 15.6 Hz, 1H, α-H), 7.74 (d, J = 15.6 Hz, 1H, β-H), 8.04-8.09 (m, 2H, 2`-H).
1-(2,5-Difluoro)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (9) <CF 1-68>
General Procedure A was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4906 g, 2.5 mmol) and
2,5-difluoroacetophenone (320 µL, 2.5 mmol) to afford a solution of a bright yellow color. After 30 min,
the solution was filtered by vacuum filtration to provide the product (0.2363 g, 28%) as a yellow solid:

mp 103-104ºC; Rf 0.76 (1:1 EtOAc/Hexane); GC/MS at 100% pure (M+ 334.1). 1H (300.13 MHz, CDCl3)
δ 3.83 (s, 3H, OCH3), 3.84 (s, 6H, OCH3), 6.78 (s, 2H, 2-H), 7.07 (m, 1H, 2`-H or 3`-H), 7.16 (d, J = 15.6,
1H, α-H), 7.21 (d, J = 15.7, 1H, β-H), 7.43 (septet, J = 2.8, 1H, 2`-H or 3`-H), 7.60 (dd, J = 1.83, 15.6,
1H, 1`-H).
1-(2,6-Difluoro)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10) <CF 1-48>
General Procedure A was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.5091 g, 2.6 mmol) and
2,6-difluoroacetophenone (330 µL, 2.5 mmol) to afford a solution of a bright yellow color. The solution
was filtered by vacuum filtration to provide the product (0.6020 g) as a pale yellow solid. The product
was triturated with 16 mL of ethanol for 1 hour to provide the product (0.3008 g, 36%) as a yellow solid:
mp 124-126ºC; Rf 0.50 (DCM); GC/MS at 99% pure (M+ 334.1); 1H (300.13 MHz, CDCl3) δ 3.90 (s,
3H, OCH3), 3.90 (s, 6H, OCH3) 6.80 (s, 2H, 2-H), 6.89 (d, J = 16.0 Hz, 1H, α-H), 7.02 (apparent t, J =
8.1 Hz, 2H, 3`-H), 7.40 (d, J = 16.2 Hz, 1H, β-H), 7.40-7.50 (m, 1H, 4`-H).
1-(2-Trifluoromethyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (11) <AMP 1-27>
General Procedure B was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4900 g, 2.49 mmol) and
2-trifluoromethyl acetophenone (380 µL, 2.5 mmol) to afford a solution of a yellow color. After 10 min,
the solution was filtered by vacuum filtration to provide the product (0.5502 g, 60%) as a light yellow
solid: mp 156-157ºC; Rf 0.74 (1:1 EtOAc/Hexane); GC/MS at 100% pure (M+ 366.1); 1H (300.13 MHz,
CDCl3) δ 3.89 (s, 6H, OCH3), 3.90 (s, 3H, OCH3), 6.76 (s, 2H, 2-H), 6.96 (d, J = 16.2 Hz, 1H, α-H),
7.20 (d, J = 16.2 Hz, 1H, β-H), 7.48 (dd, J = 1.0 Hz, 6.9 Hz, 1H, 3`-H), 7.60-7.70 (m, 2H, 4`-H), 7.79 (d,
J = 7.3 Hz, 1H, 6`-H).
1-(2-Pyridyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (12) <CF 1-30>
General Procedure A was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4906 g, 2.5 mmol) and
2-acetyl pyridine (280 µL, 2.5 mmol) to afford a solution of a bright yellow color. After 4 hours, was
filtered by vacuum filtration to provide the product (0.4605 g, 62%) as a bright yellow solid: mp 156-

157ºC (lit. mp32 115ºC); Rf 0.58 (1:1 EtOAc/Hexane); GC/MS at 98.4% pure (M+ 299.1); 1H (300.13
MHz, CDCl3) δ 3.92 (s, 3H, OCH3), 3.96 (s, 6H, OCH3), 6.97 (s, 2H, 2-H), 7.52 (ddd, J = 1.2 Hz, 4.8
Hz, 7.5 Hz, 1H, 5`-H) 7.89 (d, J = 16.0 Hz, 1H, α-H), 7.91 (td, J = 1.8 Hz, 7.7 Hz, 1H, 4`-H), 8.19 (d, J
= 15.9 Hz, 1H, β-H), 8.22 (dt, J = 1.0 Hz, 7.8 Hz, 1H, 6`-H), 8.78 (dq, J = 0.8 Hz, 4.7 Hz, 1H, 3`-H).
1-(4-Amino)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (13) <CM 1-139>
General Procedure B was carried out utilizing 3,4,5-trimethoxybenzaldehyde (0.4909 g, 2.5 mmol) and
4-aminoacetophenone (0.3380 g, 2.5 mmol) suspended in ethanol (2.5 mL). The solution was filtered by
vacuum filtration to provide the product (0.5149 g, 66%) as a yellow solid: Rf 0.30 (1:1 EtOAc/Hexane);
GC/MS at 98.9% pure (M+ 313.1); 1H (300.13 MHz, CDCl3) δ: 3.90 (s, 3H, OCH3), 3.92 (s, 6H, OCH3),
4.27 (s, 2H, NH2), 6.71 (d, J = 8.6 Hz, 2H, 2`-H), 6.86 (s, 2H, 2-H), 7.43 (d, J = 15.6 Hz, 1H, α-H), 7.70
(d, J = 15.5 Hz, 1H, β-H), 7.94 (d, J = 8.5 Hz, 2H, 3`-H).
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